Physician profile
James M Fuller
NPI 1689688301
$4,450.23
in general payments reported to CMS, 2019-2025
41 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $314 · 2021: $522 · 2022: $748 · 2023: $1,184 · 2024: $596 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,997.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $546.25 | 2019-2025 | |
| Amgen INC. | $527.11 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $387.13 | 2019-2024 | Xarelto |
| Abbott Laboratories | $327.34 | 2019-2025 | Cardiomems, Mitraclip, Gallant |
| E.R. Squibb & Sons, L.L.C. | $291.06 | 2019-2025 | Camzyos |
| Boston Scientific Corporation | $196.68 | 2019-2024 | Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $174.40 | 2019-2025 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $167.72 | 2021-2025 | Verquvo, Proquad, Capvaxive |
| Philips North America LLC | $149.30 | 2023-2024 | (5091) Amb Mon & Diag Und |
| Atricure, INC. | $144.34 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $136.07 | 2019-2023 | Lifevest |
| Abiomed | $134.43 | 2019-2024 | Impella |
| Lilly USA, LLC | $111.64 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Inari Medical, INC. | $102.83 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.43 | 2023-2024 | Jardiance |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.